Sun Pharma Advanced Research Company Limited — PPTs, 24-12-2024: Investor Presentation

SPARC's recent investor call provided insights into its clinical programs and R&D pipeline. The company continues to emphasize a strategic focus on two key therapeutic areas: Oncology and Immunology, with specific emphasis on their lead programs SCD-153 and SBO-154.

SCD-153, a topical treatment for Alopecia Areata, has shown promise in preclinical models, demonstrating hair regrowth and reduced T cell infiltration. A Phase IB study in patients is anticipated to begin in early FY26, with interim results expected in Q1 FY27.

Meanwhile, SBO-154, an anti-MUC-1 ADC, is targeting advanced solid tumors. The latest data highlights its ability to effectively target tumors with high expression of the SEA domain of MUC-1, which was validated in preclinical studies. An IND filing for this program is expected by the end of Q4 FY2025, followed by a Phase 1 study initiation soon after.

The company is actively exploring partnerships for early-stage assets and assessing short-term milestones to generate cash flow, including a potential pediatric rare disease voucher for Sezaby and a commercialization partnership for Vodobatinib. Solidifying these avenues could improve SPARC's financial outlook amidst ongoing developments in its clinical pipeline. Investors should monitor these milestones closely for positive outcomes and future growth potential.